Nogapendekin
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
Journal: BJU international
Published: July 28, 2026
Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary Disease.
Journal: The Journal of urology
Published: July 06, 2026
Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.
Journal: The Urologic clinics of North America
Published: June 26, 2026
Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.
Journal: Frontiers in immunology
Published: May 31, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
Journal: Journal of medical economics
Published: April 21, 2026
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.
Journal: Journal of medical economics
Published: March 04, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).
Journal: Frontiers in immunology
Published: February 11, 2026
Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.
Journal: Frontiers in immunology
Published: January 19, 2026
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
Journal: Cancers
Published: December 31, 2025
Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Journal: Frontiers in bioscience (Landmark edition)
Published: October 23, 2025
Intravesical gemcitabine (Inlexzo) for bladder cancer.
Journal: The Medical letter on drugs and therapeutics
Published: October 21, 2025
A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
Journal: Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
Published: October 20, 2025
Last Updated: 09/26/2026